Literature DB >> 28233640

Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.

Brittany C Parker Kerrigan1, Yuzaburo Shimizu2, Michael Andreeff3, Frederick F Lang4.   

Abstract

Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adenovirus; gliomas; mesenchymal stem cell; mesenchymal stromal cell

Mesh：

Substances：

Year:  2017        PMID： 28233640      PMCID： PMC5410175          DOI： 10.1016/j.jcyt.2017.02.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


  131 in total

1.  Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.

Authors:  Ann H Klopp; Yan Zhang; Travis Solley; Felipe Amaya-Manzanares; Frank Marini; Michael Andreeff; Bisrat Debeb; Wendy Woodward; Rosemarie Schmandt; Russell Broaddus; Karen Lu; Mikhail G Kolonin
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

2.  Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma.

Authors:  Mariam A Stoff-Khalili; Angel A Rivera; J Michael Mathis; N Sanjib Banerjee; Amanda S Moon; A Hess; Rodney P Rocconi; T Michael Numnum; M Everts; Louise T Chow; Joanne T Douglas; Gene P Siegal; Zeng B Zhu; Hans Georg Bender; Peter Dall; Alexander Stoff; Larissa Pereboeva; David T Curiel
Journal:  Breast Cancer Res Treat       Date:  2007-01-13       Impact factor: 4.872

3.  First Approval of Regenerative Medical Products under the PMD Act in Japan.

Authors:  Akihide Konishi; Ken Sakushima; Soichiro Isobe; Daisaku Sato
Journal:  Cell Stem Cell       Date:  2016-04-07       Impact factor: 24.633

Review 4.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

5.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

Authors:  Ilkka Liikanen; Laura Ahtiainen; Mari L M Hirvinen; Simona Bramante; Vincenzo Cerullo; Petri Nokisalmi; Otto Hemminki; Iulia Diaconu; Sari Pesonen; Anniina Koski; Lotta Kangasniemi; Saila K Pesonen; Minna Oksanen; Leena Laasonen; Kaarina Partanen; Timo Joensuu; Fang Zhao; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Authors:  S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

8.  Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.

Authors:  Daniel Bexell; Salina Gunnarsson; Ariane Tormin; Anna Darabi; David Gisselsson; Laurent Roybon; Stefan Scheding; Johan Bengzon
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

9.  Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.

Authors:  Jula Veerapong; Kai A Bickenbach; Michael Y Shao; Kerrington D Smith; Mitchell C Posner; Bernard Roizman; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

10.  Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.

Authors:  R A Morshed; M Gutova; J Juliano; M E Barish; A Hawkins-Daarud; D Oganesyan; K Vazgen; T Yang; A Annala; A U Ahmed; K S Aboody; K R Swanson; R A Moats; M S Lesniak
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987
View more
  17 in total

1.  Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates.

Authors:  Yizheng Yao; Jun Wang; Yi Liu; Yuan Qu; Kaikai Wang; Yang Zhang; Yuxin Chang; Zhi Yang; Jie Wan; Junfeng Liu; Hiroshi Nakashima; Sean E Lawler; E Antonio Chiocca; Choi-Fong Cho; Fengfeng Bei
Journal:  Nat Biomed Eng       Date:  2022-10-10       Impact factor: 29.234

2.  Intrathecal Injection of SIRT1-modified Human Mesenchymal Stem Cells Alleviates Neuropathic Pain in Rat.

Authors:  Jun Tian; Tieying Song; Hong Wang; Wenli Wang; Zaiwang Zhang; Ruyu Yan; Xiaojing Ma; Yue Hu
Journal:  J Mol Neurosci       Date:  2020-10-02       Impact factor: 3.444

3.  Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas.

Authors:  Frederick M Lang; Anwar Hossain; Joy Gumin; Eric N Momin; Yuzaburo Shimizu; Dan Ledbetter; Tal Shahar; Shinji Yamashita; Brittany Parker Kerrigan; Juan Fueyo; Raymond Sawaya; Frederick F Lang
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

4.  Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats.

Authors:  Chunlei Li; Yanxia Fu; Yinyin Wang; Yanhua Kong; Mengdi Li; Danhui Ma; Wanli Zhai; Hao Wang; Yuting Lin; Sihan Liu; Fangli Ren; Jun Li; Yi Wang
Journal:  Cell Biochem Funct       Date:  2017-09-20       Impact factor: 3.685

Review 5.  Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.

Authors:  Qing Zhang; Fusheng Liu
Journal:  Cell Death Dis       Date:  2020-06-25       Impact factor: 8.469

6.  Tropism of mesenchymal stem cell toward CD133+ stem cell of glioblastoma in vitro and promote tumor proliferation in vivo.

Authors:  Lorena Favaro Pavon; Tatiana Tais Sibov; Andrea Vieira de Souza; Edgar Ferreira da Cruz; Suzana M F Malheiros; Francisco Romero Cabral; Jean Gabriel de Souza; Pamela Boufleur; Daniela Mara de Oliveira; Silvia Regina Caminada de Toledo; Luciana C Marti; Jackeline Moraes Malheiros; Fernando F Paiva; Alberto Tannús; Sérgio Mascarenhas de Oliveira; Ana Marisa Chudzinski-Tavassi; Manoel A de Paiva Neto; Sérgio Cavalheiro
Journal:  Stem Cell Res Ther       Date:  2018-11-09       Impact factor: 6.832

Review 7.  Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.

Authors:  Kamal Shaik Fakiruddin; Nadiah Ghazalli; Moon Nian Lim; Zubaidah Zakaria; Syahril Abdullah
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

8.  MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice.

Authors:  Seyed-Mahmood Seyed-Khorrami; Hoorieh Soleimanjahi; Sara Soudi; Ala Habibian
Journal:  Cancer Cell Int       Date:  2021-05-01       Impact factor: 5.722

Review 9.  Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.

Authors:  Qing Zhang; Wei Xiang; Dong-Ye Yi; Bing-Zhou Xue; Wan-Wan Wen; Ahmed Abdelmaksoud; Nan-Xiang Xiong; Xiao-Bing Jiang; Hong-Yang Zhao; Peng Fu
Journal:  Stem Cell Res Ther       Date:  2018-08-24       Impact factor: 6.832

10.  Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.

Authors:  Mohsen Keshavarz; Mir Saeed Ebrahimzadeh; Seyed Mohammad Miri; Hassan Dianat-Moghadam; Seyedeh Sara Ghorbanhosseini; Seyed Reza Mohebbi; Hossein Keyvani; Amir Ghaemi
Journal:  Virol J       Date:  2020-05-05       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.